Publications in collaboration with researchers from Charité (14)

2025

  1. Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures

    Nature Reviews Cardiology, Vol. 22, Núm. 4, pp. 273-303

2024

  1. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study

    Critical care medicine, Vol. 52, Núm. 6, pp. 930-941

2022

  1. Acute Myocarditis Associated With Desmosomal Gene Variants

    JACC: Heart Failure, Vol. 10, Núm. 10, pp. 714-727

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  3. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

    European Heart Journal, Vol. 42, Núm. 31, pp. 3011-3020

  4. The interpretation of CHA2DS2-VASc score components in clinical practice: A joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA young Electrophysiologists, the association of cardiovascular nursing and Allied professionals, and the European society of cardiology council on stroke

    Europace, Vol. 23, Núm. 2, pp. 314-322

2020

  1. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

    The Lancet, Vol. 396, Núm. 10266, pp. 1895-1904

2019

  1. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure

    European Journal of Heart Failure, Vol. 21, Núm. 12, pp. 1651-1658

  2. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184

  2. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

    European Heart Journal, Vol. 34, Núm. 33, pp. 2636-2648

2012

  1. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis

    European Journal of Heart Failure, Vol. 14, Núm. 7, pp. 681-695

  2. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: An executive summary# of a joint consensus document from the ESC heart failure association and the esc working group on thrombosis

    Thrombosis and Haemostasis, Vol. 108, Núm. 6, pp. 1009-1022